Two obesity drugs reimbursed from 15 June

The 2 drug treatments of obesity (TMO) Wegovy and Mounjaro will be covered by the Health Insurance from 15 june 2026under certain conditions. These injectable treatments, originally developed for diabetes, are analogs of GLP-1, a family of drugs that slow digestion and increase the feeling of satiety.

These medicines have been available in France since 2024 and are dispensed by prescription at a price set by the laboratory, without reimbursement possible by the Health Insurance.

Which patients are eligible for treatment?

Patients eligible for reimbursement for these treatments are those eligible for bariatric surgery (surgery to achieve significant weight loss through changes to the digestive tract). The following are concerned:

• people with a body mass index (BMI) 40 or more (massive obesity) without comorbidity ;
• people with a BMI 35 or more (severe obesity) with comorbidity.

This type of treatment can only be prescribed as a second-line treatment, in case of failure of nutritional management (i.e. a weight loss of 5% of the total weight after 6 months). He has to intervene in addition to a low-calorie diet and increased physical activity.

Who needs to prescribe this type of medication for it to be reimbursed?

The initial prescription of the drug is reserved for professionals and structures involved in the management of obesity at levels 2 and 3 : doctors practicing in specialized obesity centers (CSO); university hospitals (CHU); medical care and rehabilitation institutions (SMR) of gastroenterology, endocrinology, diabetes, nutrition; endocrinologists in connection with a CSO.

What financial support?

The insured person's participation rate is set at 35%, i.e 65% coverage by the Health Insurance. The possibility of full coverage will have to be checked on a case-by-case basis, depending on the status of the insured, a possible long-term illness (ALD), the applicable exemptions and the possession of supplementary health.